Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
|
|
- Charlotte Richard
- 6 years ago
- Views:
Transcription
1 Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko Iwasawa 2, Kenji Fujimori 3, Tadashi Hasegawa 4 and Taiji Tsukamoto 1 1 Department of Urology, Sapporo Medical University School of Medicine, Sapporo, 2 Iwasawa Clinic, Sapporo, 3 Department of Radiology, Sapporo Medical University School of Medicine, Sapporo and 4 Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan Received March 8, 2007; accepted June 11, 2007; published online October 2, 2007 Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym097 Background: We evaluated the relationship between serum PSA and clinical variables to eliminate bone scanning in patients with prostate cancer having a low probability of bone metastasis. Methods: The study included 366 patients with newly diagnosed prostate cancer between 1999 and Bone metastasis was studied for its correlation with various clinical and pathological variables in these patients. Results: Bone metastasis was found in 28 (7.7%) of 366 patients. Fourteen patients had skeletal symptoms related to bone metastasis. The risk for bone metastases increased considerably with increases of PSA level, clinical T stage and Gleason score. The metastasis was not found in 161 patients with serum PSA concentration of 10 ng/ml or lower. In 95 patients with the concentration between 10 and 20 ng/ml only two had the metastasis. These two patients had T2 disease and Gleason scores of 7 or greater. In 204 patients with clinical stage T1 disease, one (0.5%) had the metastasis. In 117 patients with Gleason scores of 6 or less, the metastasis was found in two (1.7%). Conclusions: For patients with serum PSA levels of 10 ng/ml or lower, bone scanning may be eliminated because of the negligible risk of bone metastases. In addition, scanning may not be necessary for those with PSA levels between 10 and 20 ng/ml, when they have T1 disease and Gleason scores of 6 or lower. Key words: bone scan prostatic-specific antigen prostate cancer INTRODUCTION Bone scanning has been routinely used to detect bone metastasis for patients with newly diagnosed prostate cancer. However, it is an expensive and time-consuming staging modality. In the era of prostate-specific antigen (PSA), the number of patients who have bone metastasis or local extension of the disease at diagnosis has been decreasing, and most patients with the disease tend to have a low risk for bone metastasis. Today, the American Urological Association guideline states that routine use of bone scanning may not be required for staging asymptomatic patients who have clinically localized disease that is newly diagnosed, when their PSA is equal to For reprints and all correspondence: Taiji Tsukamoto, Department of Urology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-Ku, Sapporo , Japan. taijit@sapmed.ac.jp or less than 20.0 ng/ml (1). The European Association of Urology guideline for prostate cancer suggests that bone scintigraphy may not be indicated in asymptomatic patients, if the serum PSA level is less than 20 ng/ml in the presence of well or moderately differentiated tumors (2). These guidelines were followed by the publication of a clinical guideline for prostate cancer by the Japanese Urological Association in 2006 (3). The guideline indicates that bone scanning can be eliminated for patients with PSA of 10 ng/ml or less who have well or moderately differentiated carcinoma. However, the guideline also suggests that it does not necessarily exclude the use of bone scanning even for such patients. In addition, a recent review article recommended the use of bone scanning for patients with PSA concentrations greater than 10 ng/ml (4). Thus, the controversy still exists. Unfortunately, because there are only a few Japanese studies on the # 2007 Foundation for Promotion of Cancer Research
2 Jpn J Clin Oncol 2007;37(10) 789 issue, the situation does not allow us to draw a concrete conclusion (5, 6). In this study, we evaluated the relationship between bone metastasis and clinical or pathological variables, including the serum PSA concentration, in patients with newly diagnosed prostate cancer. With the evaluation, we tried to determine the clinical profiles of patients for whom bone scanning could be eliminated due to a low probability of bone metastasis. PATIENTS AND METHODS PATIENT POPULATION This retrospective study included 366 consecutive patients with newly diagnosed adenocarcinoma of the prostate ( prostate cancer), who visited Sapporo Medical University Hospital or the Iwasawa Clinic between January 1999 and September All needle biopsy specimens of the prostate were evaluated by surgical pathologists in the university hospital. Bone scans were done in the Diagnostic Radiology department of the hospital according to the procedures described below. The study did not include patients who had a past history of antiandrogen treatment for benign prostatic hyperplasia or that of other malignant diseases with possible development of bone metastasis. CLINICAL DATA We thoroughly reviewed the local clinical stage, histological grade, serum PSA concentration and skeletal symptoms. The local clinical T stage was determined with digital rectal examination and transrectal ultrasonography before prostate biopsy, and was categorized according to the TNM classification of malignant tumors (7). All but eight patients underwent transrectal systematic biopsies for diagnosis of the disease. In the biopsy, three to seven cores from each prostatic lobe with a total of six to 14 cores were taken and served for diagnosis. In the other eight patients, prostate cancer was diagnosed by pathological examination of specimens from transurethral resection of the prostate done for relief of bladder outlet obstruction. Histological grading of all specimens was evaluated according to the Gleason grading system. The rate of positive biopsy cores was determined by the following formula: the number of positive cores/the number of total biopsy cores. The serum concentration of PSA was determined by the Tandem-R PSA, monoclonal immunoradiometric assay with the normal range set between 0 and 4.0 ng/ml. BONE SCANS Bone scans and computed tomography (CT) of the pelvis were done in all patients for the initial evaluation of bone or lymph node metastasis. All bone scans were performed with standard procedures. Patients were intravenously given 555 MBq Technetium-99m ( 99m Tc) methylene diphosphonate (MDP). One of the authors (K.F.), who specialized in nuclear medicine, evaluated the findings of bone scans and made a tentative diagnosis as positive, negative or equivocal. In the latter diagnosis, plain X-rays, CT or magnetic resonance imaging (MRI) was additionally used to establish the final diagnosis. Thus, a positive bone scan was prudently interpreted as bone metastasis. STATISTICAL ANALYSIS Statistical significance between serum PSA and other clinical variables was determined with the Mann Whitney U-test and P, 0.05 was considered to be statistically significant. RESULTS The patients characteristics at the time of diagnosis are summarized in Table 1. More than 75% of the patients were examined between 2002 and The median age of patients was 71 years (range, years). The median serum concentration of PSA was 11.7 ng/ml, which reflected the recent trend of stage migration of the disease to an earlier one. More than 80% of the patients were diagnosed as having clinically localized disease. However, 10% of patients had either lymph node metastasis or distant metastasis. Bone scan findings were tentatively classified into three categories, positive in 16 patients, negative in 300 patients and equivocal in 50 patients. Further work-up finally revealed that 28 patients (7.7%) had bone metastasis of the disease. The relationship between bone metastasis and clinical variables is shown in Table 2. Of the 28 patients with bone metastasis, 14 (50%) had skeletal symptoms such as lumbago and leg pain relating to the metastasis. The prevalence of metastasis increased apparently with the elevation of the serum PSA level and progression of the clinical T stage. Bone metastasis was not found in patients with serum PSA equal to or less than 10 ng/ml. However, 42.3% of Table 1. Patients characteristics and clinical stage at diagnosis Clinical variables Number of patients 366 Median age (years) 71 (43 79) Median PSA (ng/ml) 11.7 ( ) Clinical T stage T1N0M0 203 (55.5%) T2N0M0 96 (26.2%) T3-4N0M0 30 (8.2%) Any T, Nþ, M0 5 (1.4%) Any T, any N, Mþ 32 (8.7%) PSA, prostate-specific antigen.
3 790 Bone scan for newly diagnosed prostate cancer Table 2. Relationship between bone metastasis and clinical variables Variables Total Bone metastasis P value Negative Positive (%) Number of patients (7.7) Bone symptoms without (4.1),0.001 with (63.6) Serum PSA (ng/ml) (0) (2.1), (6.9) (42.3) Clinical T stage T1a/b (0) T1c (0.5),0.001 T (5.8) T3 or T (35.6) Table 3. Relationship between bone metastasis and pathological variables Variables Total Bone Scan P value Negative Positive (%) Number of patients (7.7) Gleason score (0) (2.3) (5.9), (11.1) (22.9) unknown Rate of positive biopsy cores (%) (0) (3.7), (2.5) (26.5) Uknown patients had the metastasis when their serum PSA was higher than 50.0 ng/ml. If we used a PSA level of 10 ng/ml or lower as the cutoff value, the negative predictive value was 100%. Since patients with this category of PSA comprised only less than 50% of all patients, the category was extended to those with a level of PSA 20 ng/ml. Based on the result of bone metastasis in 256 patients who had serum PSA with 20 ng/ml or less, only two patients had the metastasis. Their serum PSA concentrations were 14.5 and 15.8 ng/ml, and had T2 disease and Gleason score 7 or greater. Thus, the negative predictive value was determined to be 99.2%, when the serum PSA concentration of 20 ng/ml or less was used as a cut-off point. As for the correlation of bone metastasis with clinical T stage, the metastasis was found in only one patient with clinical T1 disease. However, for stages T2 and T3/4 there was significant prevalence of metastasis. Among the 307 patients with T1 T2 disease, only seven patients (2.3%) had positive bone scans. Their PSA concentrations were distributed from 14.5 to 93 ng/ml, and their Gleason scores were 6 in one patient, 7 in four patients and 9 in two patients. There were no significant differences in the pathological grade or level of PSA among the patients with T1 T2 disease. In the seven patients bone metastasis was confirmed with additional CT scans or MR imaging, while two patients had obvious hot spots that undoubtedly indicated bone metastasis. Gleason grading of prostate cancer was not available for 9 patients, leaving 357 to be evaluated for the grading. Gleason score 7 was the most common grade, accounting for 51% of patients (Table 3). The risk of bone metastasis increased considerably with an increase of the Gleason score. Of 117 patients with Gleason scores of 6 or less, only two (1.7%) patients had the metastasis. Although the rate of positive biopsy core did not linearly increase as the prevalence of bone metastasis increased, it was clear that onequarter of the patients had bone metastasis when the rate of positive biopsy core exceeded 75%. DISCUSSION PSA is the most valuable tumor marker for prostate cancer and most accurately reflects the tumor status in patients with the disease. In our study, significant correlations exist between the incidence of bone metastasis and clinical variables such as the PSA level, clinical T stage, Gleason score and the rate of positive biopsy cores. Because of these correlations, bone scanning may not be necessary for patients who are at low risk for bone metastasis. Indeed, bone metastasis is significantly correlated with the PSA level. Chybowski et al. (8). documented that the PSA level was correlated with the risk of bone metastasis in 521 patients randomly selected. They suggested that the PSA concentration was the best predictor for bone metastases among other clinical and pathological parameters when the receiver operating curve was used. In that study, only one patient had bone metastases among 307 with PSA concentration of 20 ng/ml or less, indicating that the negative predictive value was 99.7%. Also, Oesterling et al. (9). evaluated 852 patients with newly diagnosed prostate cancer having PSA concentrations equal to or less than 20 ng/ml. In their large series, only seven patients (0.8%) had abnormal findings on bone scans. The result of our study is consistent with that reported by Oesterling et al. In our study, none of the 161 patients with PSA concentration of 10 ng/ml or less had bone metastases and only two of the 256 (0.8%) patients whose PSA concentrations were equal to
4 Jpn J Clin Oncol 2007;37(10) 791 or less than 20.0 ng/ml had bone metastases, with a 99.2% negative predictive value. Several studies, however, raised the question of whether a staging bone scan could be omitted for patients with PSA concentrations of 20 ng/ml or less. Wolff et al. (10) retrospectively studied 359 patients, and they found that, of 40 patients with bone metastases, seven (17.5%) patients had PSA concentrations of 10 ng/ml or less. Their results gave an estimated negative predictive value of 96%. A multicenter study done in Japan reported that positive bone scans were found in four (1.3%) of 300 patients whose PSA concentrations were equal to or less than 10 ng/ml. (5). However, it must be noted that these studies had lower proportions of patients with clinically localized disease than our study. In contrast, recent patients are diagnosed at an earlier stage and with lower PSA levels than before. Thus, it may be valid for bone scans to be eliminated for patients with low PSA levels in the current practice. The risk for bone metastasis increases with higher clinical stage and higher tumor grade. Gleave et al. (11) reported that the rates of positive bone scan were 19% in T3 disease, 1% in T2 and 4% in T1 among 490 patients who were eligible for evaluation. They also mentioned that the negative predictive value of clinical T stage and tumor grade were insufficient to identify the patients with a low risk for bone metastases. Consequently, they recommended that bone scans be indicated in patients with PSA concentrations of 10 ng/ml or greater, clinical T3 or poorly differentiated disease. In our series, bone metastasis was found in only two patients with PSA concentrations of 20 ng/ml or less and no skeletal symptoms. Since they had T2 disease and Gleason scores of 7 or greater, incorporation of the clinical T stage and Gleason score into prediction of bone metastasis may have avoided making a misdiagnosis of not having metastasis in patients with PSA concentrations between 10 and 20 ng/ml. Based on our results, bone scanning may be safely eliminated for patients with PSA concentrations of 10 ng/ml or less. In addition, scanning may not be necessary for patients with serum PSA between 10 and 20 ng/ml, when they have T1 disease and Gleason scores of 6 or lower. However, in those with serum PSA between 10 and 20 ng/ml, the scanning may be offered, when they have T2 or more advanced disease, or Gleason scores of 7 or greater. In our study, these criteria allow 52% of the total patients to avoid bone scanning. In this study, because the rate of positive biopsy cores was strongly correlated with tumor volume, the rate was incorporated with the PSA cutoff point in addition to the Gleason score and tumor grade. However, nonlinear correlation of the rate with the incidence of bone metastasis did not support the use of predictive factors for eliminating bone scan. An important limitation of the present study is its relatively small study population and the few patients with bone metastases. Only 28 of 366 patients (7.7%) had bone metastases at diagnosis. On the other hand, the cancer registration committee of the Japanese Urological Association reported the clinical data of 4529 prostate cancer patients in Japan (12). The report indicated that almost 20% of patients had bone metastases. This result indicates that the patients in the present study may not necessarily reflect the entire population having prostate cancer in Japan. This discrepancy may be partly explained by the fact that more than 75% of the patients in the study visited us between 2002 and 2005, indicating that they might have had earlier-stage disease than those before The current results should be validated prospectively in a larger number of patients. The second issue for the limitation may be the diagnosis basedongleasonscore.overthe years, there has been a controversy about diagnosis for a low grade adenocarcinoma based on needle biopsy. Epstein (13) noted that low-grade prostate cancers with Gleason scores of 2 4 should not be diagnosed on needle biopsy because of the possible underestimation of a high-grade tumor and the poor reproducibility in the diagnosis. Recently an international conference was held to establish a consensus on the controversy related to the Gleason grading system (14). In this context, low-grade Gleason scores in previous studies should be re-evaluated with the contemporary definition. In our study, the majority of patients (92%) had Gleason scores of 6 or more, which fits with the current trend for the distribution of Gleason scores. CONCLUSIONS For patients with serum PSA levels of 10 ng/ml or lower, bone scanning may be eliminated because of the negligible risk of bone metastases. Scanning may not be necessary for those with PSA levels between 10 and 20 ng/ml, when they have T1 disease and Gleason scores of 6 or lower. Conflict of interest statement None declared. References 1. PSA Best Practice Policy Task Force from the American Urological Association. Prostate-Specific Antigen (PSA) Best Practice Policy Aus G, Abbou CC, Bolla M, Heidenreich A, van Poppel H, Schmid H-P, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48: The Japanese Urological Association. Prostate Cancer: Clinical Practice Guideline. Tokyo: Kanehara Shuppan Kabushikikaisha, 2006; (in Japanese). 4. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243: Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akaza K, Kuyama J, et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? Cancer 2002;94: Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kinebuchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol 2005;12:
5 792 Bone scan for newly diagnosed prostate cancer 7. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss, Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oestering JE. Predicting radionuclide bone scan finding in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. JUrol1991;145: Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostatespecific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269: Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33: Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, et al. Ability of serum prostate-specific antigen levels to predict normal bone scan in patients with newly diagnosed prostate cancer. Urology 1996;47: Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12: Epstein JI. Gleason score 2 4 adenocarcinoma of the prostate on needle biopsy; a diagnosis that should be made. Am J Surg Pathol 2000;24: Epstein JI, Allsbrook WC, Amin MB, Egevad LL, the ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:
GUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationUniversity of Groningen
University of Groningen Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase Wymenga, LFA; Boomsma, JHB; Groenier, K; Piers, DA; Mensink,
More informationDisease-specific death and metastasis do not occur in patients with Gleason score 6 at radical prostatectomy
Disease-specific death and metastasis do not occur in patients with at radical prostatectomy Charlotte F. Kweldam, Mark F. Wildhagen*, Chris H. Bangma* and Geert J.L.H. van Leenders Departments of Pathology,
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationResearch Article Bone Scan Is of Doubtful Value as a First Staging Test in the Primary Presentation of Prostate Cancer
International Scholarly Research Network ISRN Oncology Volume 2012, Article ID 585017, 6 pages doi:10.5402/2012/585017 Research Article Bone Scan Is of Doubtful Value as a First Staging Test in the Primary
More informationExamining the value PSA=10ng/ml as a cutoff for predicting metastatic bone disease in NaF18 PET/CT bone scans, a pilot study
ORIGINAL RESEARCH Examining the value PSA=10ng/ml as a cutoff for predicting metastatic bone disease in NaF18 PET/CT bone scans, a pilot study Aung Z. Win 1, Carina M. Aparici 2 1. Dept. Radiology, Nuclear
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationKoji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto
Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationTopics: Staging and treatment for pancreatic cancer. Staging systems for pancreatic cancer: Differences between the Japanese and UICC systems
M. J Hep Kobari Bil Pancr and S. Surg Matsuno: (1998) Staging 5:121 127 system for pancreatic cancer 121 Topics: Staging and treatment for pancreatic cancer Staging systems for pancreatic cancer: Differences
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationScreening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System
Jpn J Clin Oncol 2000;30(2)95 100 Screening for Prostate Cancer Using Prostate-specific Antigen Alone asafirst-linecheckupparameter:resultsofthehealthcheckup System Katsunori Uchida 1, Hitoshi Takeshima
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationPredictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients
RESEARCH ARTICLE Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients Tsu-Ming Chien 1,2, Yen-Man Lu 1,2, Jiun-Hung Geng 1,2, Tsung-Yi Huang 1,2, Hung- Lung Ke 1,2, Chun-Nung
More informationA Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
168) Prague Medical Report / Vol. 112 (2011) No. 3, p. 168 176 A Comparative Analysis of Primary and Secondary Gleason Pattern Predictive Ability for Positive Surgical Margins after Radical Prostatectomy
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationWhen to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
Lin et al. BMC Urology (2017) 17:41 DOI 10.1186/s12894-017-0229-z RESEARCH ARTICLE Open Access When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study
More informationEAU Guidelines on Prostate Cancer
European Urology European Urology 48 (2005) 546 551 Editorial and EAU Guideline EAU Guidelines on Prostate Cancer G. Aus a, *, C.C. Abbou b, M. Bolla c, A. Heidenreich d, H.-P. Schmid e, H. van Poppel
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationAre Prostate Carcinoma Clinical Stages T1c and T2 Similar?
Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationDiagnosis and Classification of Prostate Cancer
Patient Information English 32 Diagnosis and Classification of Prostate Cancer The underlined terms are listed in the glossary. prostate biopsy is the only test that can confirm a prostate cancer diagnosis.
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationστη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου
Η θέση του PET/CT στη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου 2014 : the Guidelines year. PRINCIPLES OF IMAGING Imaging is performed for the detection
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationDiffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence After Radical Prostatectomy: Initial Experience
EUROPEAN UROLOGY 61 (2012) 616 620 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Study of the Month Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence
More informationDIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE
32, 4, 2010, 3.,.. DIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE N. Smilov, N. Koleva and I. Lozev Medical Institute Ministry
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationMonotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationProstate Specific Antigen as a risk factor for skeletal metastasis in Black African men with Prostate Cancer: a Case Control study
Prostate Specific Antigen as a risk factor for skeletal metastasis in Black African men with Prostate Cancer: a Case Control study ABSTRACT Prostate cancer is the commonest non cutaneous cancer in males.
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationBone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When PET Scans Findings Are Equivocal: A Case Report
Bone and CT Scans Are Complementary for Diagnoses of Bone Metastases in Breast Cancer When Scans Findings Are Equivocal: A Case Report Yuk-Wah Tsang 1, Jyh-Gang Leu 2, Yen-Kung Chen 3, Kwan-Hwa Chi 1,4
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationDistant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination
Endocrine Journal 2008, 55 (5), 889 894 Distant and Lymph Node Metastases of Thyroid Nodules with No Pathological Evidence of Malignancy: A Limitation of Pathological Examination YASUHIRO ITO, TOMONORI
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More information1. Introduction. Department of Urology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba , Japan 2
Hindawi Publishing Corporation Prostate Cancer Volume 2011, Article ID 754382, 6 pages doi:10.1155/2011/754382 Clinical Study Development and External Validation of a Nomogram Predicting the Probability
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationOriginal Paper. Urol Int 2013;90: DOI: /
Urologia Internationalis Original Paper Received: January 27, 2012 Accepted after revision: November 26, 2012 Published online: February 13, 2013 Comparison of Transrectal Prostate Biopsy Results with
More informationClinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma Associated with End-stage Renal Disease
Jpn J Clin Oncol 2014;44(11)1096 1100 doi:10.1093/jjco/hyu117 Advance Access Publication 19 August 2014 Clinical Symptoms Predict Poor Overall Survival in Chronic-dialysis Patients with Renal Cell Carcinoma
More informationI have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a product in my presentation.
Prostate t Cancer MR Report Disclosure Information Vikas Kundra, M.D, Ph.D. I have no financial relationships to disclose. I WILL NOT include discussion of investigational or off-label use of a g product
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationIs Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen?
www.kjurology.org http://dx.doi.org/1.4111/kju.1.3..8 Urological Oncology Is Prostate Biopsy Essential to Diagnose Prostate Cancer in the Older Patient with Extremely High Prostate-Specific Antigen? Jee
More informationUpgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy
MOLECULAR AND CLINICAL ONCOLOGY 2: 1145-1149 Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy CAROLINA D'ELIA, MARIA ANGELA CERRUTO, ANTONIO CIOFFI, GIOVANNI NOVELLA,
More informationGeneral information about prostate cancer
Prostate Cancer General information about prostate cancer Key points Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. Signs of prostate cancer include
More informationRegional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
Original Article Prostate Int 14;2(1):19- http://dx.doi.org/.12954/pi.135 P ROSTATE INTERNATIONAL Regional difference in cancer detection rate in prostate cancer screening by a local municipality in Japan
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationProstate cancer presents in various ways, including
Case Report 840 Presentation of Prostate Carcinoma with Cervical Lymphadenopathy: Report of Three Cases Hung-Jen Wang, MD; Po-Hui Chiang, PhD; Jyh-Ping Peng 1, MD; Tsan-Jeng Yu, MD The most common method
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationMetastatic mechanism of spermatic cord tumor from stomach cancer
Int Canc Conf J (2013) 2:191 195 DOI 10.1007/s13691-013-0-9 CANCER BOARD CONFERENCE Metastatic mechanism of spermatic cord tumor from stomach cancer Masahiro Seike Yoshikazu Kanazawa Ryuji Ohashi Tadashi
More informationTHE DILEMMA OF PROSTATE CANcer
ORIGINAL CONTRIBUTION Biological Determinants of Cancer Progression in Men With Prostate Cancer Thomas A. Stamey, MD John E. McNeal, MD Cheryl M. Yemoto Bronislava M. Sigal, PhD Iain M. Johnstone, PhD
More informationIn 2005, International Society of Urological Pathology
ORIGINAL ARTICLE Gleason Score 3+4=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen Cheng Cheng Huang, MD,*
More informationDiagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer
ONCOLOGY LETTERS 7: 2013-2018, 2014 Diagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer YIYAN LIU Nuclear Medicine Service, Department of Radiology,
More informationGlossary of Terms Primary Urethral Cancer
Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,
More informationLong-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific Antigen over 500 ng/ml
Jpn J Clin Oncol 2014;44(12)1227 1232 doi:10.1093/jjco/hyu142 Advance Access Publication 19 September 2014 Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More information